Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 23

Results For "Covid"

1150 News Found

Zymo Research donates one million Covid-19 test kits to Mapmygenome
News | September 28, 2021

Zymo Research donates one million Covid-19 test kits to Mapmygenome

Its DirectDetect reagent eliminates RNA extraction for rapid deployment of Covid-19 tests in affected countries


SAB Biotherapeutics’ SAB-185 moves to Phase 3 trial for Covid-19 treatment
Biotech | September 26, 2021

SAB Biotherapeutics’ SAB-185 moves to Phase 3 trial for Covid-19 treatment

Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors


Novavax and Serum seek WHO approval for Covid-19 vaccine
News | September 24, 2021

Novavax and Serum seek WHO approval for Covid-19 vaccine

It is a recombinant nanoparticle protein-based vaccine


Health Minister Mansukh Mandaviya releases post-Covid sequelae modules
Public Health | September 23, 2021

Health Minister Mansukh Mandaviya releases post-Covid sequelae modules

These modules will act as a guide to doctors and health care workers to deal with post-Covid-19 issues


Pfizer and BioNTech receive U.S. FDA EUA for Covid-19 booster
Drug Approval | September 23, 2021

Pfizer and BioNTech receive U.S. FDA EUA for Covid-19 booster

Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups


DCGI approves Ampio Pharma’s Phase II trials to tackle Covid-19 induced respiratory distress
Biotech | September 22, 2021

DCGI approves Ampio Pharma’s Phase II trials to tackle Covid-19 induced respiratory distress

Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs


Pfizer and BioNTech’s Covid-19 vaccine safe for children aged 5 to 11: study
Biotech | September 21, 2021

Pfizer and BioNTech’s Covid-19 vaccine safe for children aged 5 to 11: study

In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year


India to resume export of Covid-19 vaccines from October
Policy | September 20, 2021

India to resume export of Covid-19 vaccines from October

The country’s vaccine production has more than doubled since April and is set to touch 300 million doses next month


India extends concession on life-saving Covid-19 drugs till December 2021
News | September 18, 2021

India extends concession on life-saving Covid-19 drugs till December 2021

The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines


LifeCell receives DCGI approval for Mesocel clinical trial to treat Covid-19
Biotech | September 17, 2021

LifeCell receives DCGI approval for Mesocel clinical trial to treat Covid-19

The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19